FindTrial
Sign In

The predictive value of prostate central gland/total gland volume ratio combined with PSA and Imaging examination in PSA 4-20ng/ml prostate cancer patients

The predictive value of prostate central gland/total gland volume ratio combined with PSA and Imaging examination in PSA 4-20ng/ml prostate cancer patients

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2000030040
Enrollment
Unknown
Registered
2020-02-21
Start date
2020-03-01
Completion date
Unknown
Last updated
2024-12-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Prostate cancer

Interventions

Gold Standard:Needle biopsy
Index test:prostate central gland/total gland volume ratio combined with PSA and Imaging examination

Sponsors

MinHang Hospital, Fudan University
Lead Sponsor

Eligibility

Sex/Gender
Male
Age
55 Years to 85 Years

Inclusion criteria

Inclusion criteria: 1. Male; 2. Aged 55-85 years; 3. PSA 4-20ng/ml, accord with the index of prostate biopsy.

Exclusion criteria

Exclusion criteria: 1. Using 5a-RIs; 2. Urinary tract infrction within the past month; 3. Urinary tract operation within the past month; 4. Serious systemic disease.

Design outcomes

Primary

MeasureTime frame
outcome of prostate biopsy;SEN, SPE, ACC, AUC of ROC;—

Countries

China

Contacts

Public ContactHe Chang

Minhang Hospital, Fudan University

kubivpdefansdd@163.com+86 13818794604

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026